Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devin Incerti

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
JCO Clinical Cancer Informatics|November 21, 2025
Meta-Analysis of Bias in Non-Small Cell Lung Cancer External Control Arms That Use Real-World Progression-Free Survival as the End PointSanaa Bahmane, Chris Harbron, Devin Incerti, et al.
MDM Policy & Practice|October 6, 2018
The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United StatesDevin Incerti, Nicholas Summers, Thanh G N Ton, et al.
Journal of Medical Economics|July 21, 2017
Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1aMelissa A Frasco, Tiffany Shih, Devin Incerti, et al.
BMJ Open|April 8, 2021
Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USADevin Incerti, Shemra Rizzo, Xiao Li, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseasesDevin Incerti, Xiang-Ming Xu, Jacquelyn W Chou, et al.
BMC Health Services Research|February 13, 2019
An empirical tool for estimating the share of unmet need due to healthcare inefficiencies, suboptimal access, and lack of effective technologiesDevin Incerti, John Browne, Caroline Huber, et al.
Journal of Medical Economics|March 16, 2017
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulatorsJeroen P Jansen, Devin Incerti, Alex Mutebi, et al.
American Journal of Perinatology|February 20, 2019
Maternal and Infant Adverse Outcomes Associated with Mild and Severe Preeclampsia during the First Year after Delivery in the United StatesThanh G N Ton, Mihoko V Bennett, Devin Incerti, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2020
The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid ArthritisDevin Incerti, Ervant J Maksabedian Hernandez, Joseph Tkacz, et al.
Plos One|February 13, 2026
Prognostic pan-cancer and single-cancer models: A large-scale analysis using a real-world clinico-genomic databaseSarah F McGough, Svetlana Lyalina, Devin Incerti, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
JCO Clinical Cancer Informatics|November 21, 2025
Meta-Analysis of Bias in Non-Small Cell Lung Cancer External Control Arms That Use Real-World Progression-Free Survival as the End PointSanaa Bahmane, Chris Harbron, Devin Incerti, et al.
MDM Policy & Practice|October 6, 2018
The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United StatesDevin Incerti, Nicholas Summers, Thanh G N Ton, et al.
Journal of Medical Economics|July 21, 2017
Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1aMelissa A Frasco, Tiffany Shih, Devin Incerti, et al.
BMJ Open|April 8, 2021
Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USADevin Incerti, Shemra Rizzo, Xiao Li, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseasesDevin Incerti, Xiang-Ming Xu, Jacquelyn W Chou, et al.
BMC Health Services Research|February 13, 2019
An empirical tool for estimating the share of unmet need due to healthcare inefficiencies, suboptimal access, and lack of effective technologiesDevin Incerti, John Browne, Caroline Huber, et al.
Journal of Medical Economics|March 16, 2017
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulatorsJeroen P Jansen, Devin Incerti, Alex Mutebi, et al.
American Journal of Perinatology|February 20, 2019
Maternal and Infant Adverse Outcomes Associated with Mild and Severe Preeclampsia during the First Year after Delivery in the United StatesThanh G N Ton, Mihoko V Bennett, Devin Incerti, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2020
The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid ArthritisDevin Incerti, Ervant J Maksabedian Hernandez, Joseph Tkacz, et al.
Plos One|February 13, 2026
Prognostic pan-cancer and single-cancer models: A large-scale analysis using a real-world clinico-genomic databaseSarah F McGough, Svetlana Lyalina, Devin Incerti, et al.
Pageof 3